nimorazole has been researched along with Cancer of Pharynx in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastholt, L; Berthelsen, A; Hansen, HS; Jørgensen, K; Lindeløv, B; Overgaard, J; Overgaard, M; Specht, L | 1 |
| Ben-Josef, E | 1 |
1 trial(s) available for nimorazole and Cancer of Pharynx
| Article | Year |
|---|---|
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
Topics: Adult; Aged; Aged, 80 and over; Cell Hypoxia; Combined Modality Therapy; Double-Blind Method; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Nimorazole; Pharyngeal Neoplasms; Placebos; Radiation-Sensitizing Agents; Salvage Therapy; Treatment Outcome | 1998 |
1 other study(ies) available for nimorazole and Cancer of Pharynx
| Article | Year |
|---|---|
Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85.
Topics: Humans; Laryngeal Neoplasms; Nimorazole; Pharyngeal Neoplasms; Radiation-Sensitizing Agents | 1998 |